Trial Outcomes & Findings for Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases (NCT NCT02336763)

NCT ID: NCT02336763

Last Updated: 2020-07-24

Results Overview

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

2 participants

Primary outcome timeframe

Up to 5 years

Results posted on

2020-07-24

Participant Flow

Participant milestones

Participant milestones
Measure
Treatment (External Beam Radiation Therapy)
Patients undergo external beam radiation therapy daily over 20 minutes on Monday-Friday for up to 10 fractions over approximately 2 weeks. External Beam Radiation Therapy: Undergo external beam radiation therapy Laboratory Biomarker Analysis: Correlative studies
Overall Study
STARTED
2
Overall Study
COMPLETED
2
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Treatment (External Beam Radiation Therapy)
n=2 Participants
Patients undergo external beam radiation therapy daily over 20 minutes on Monday-Friday for up to 10 fractions over approximately 2 weeks. External Beam Radiation Therapy: Undergo external beam radiation therapy Laboratory Biomarker Analysis: Correlative studies
Age, Categorical
<=18 years
0 Participants
n=93 Participants
Age, Categorical
Between 18 and 65 years
2 Participants
n=93 Participants
Age, Categorical
>=65 years
0 Participants
n=93 Participants
Sex: Female, Male
Female
1 Participants
n=93 Participants
Sex: Female, Male
Male
1 Participants
n=93 Participants
Region of Enrollment
United States
2 participants
n=93 Participants

PRIMARY outcome

Timeframe: Up to 5 years

Population: Study terminated early no analysis conducted. Subjects would need to be followed for up to 5 years to answer this objective. Subject 1 was followed 5 months and subject 2 was followed 2 months. Therefore, data was not collected from any subject for this Outcome Measure.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Up to 5 years

Population: study terminated early no analysis conducted. Data was not collected from any subject for this Outcome Measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Within 3 months of study treatment

Population: study terminated early no analysis conducted. Data was not collected from any subject for this Outcome Measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: More than 3 months after study treatment

Population: study terminated early no analysis conducted. Data was not collected from any subject for this Outcome Measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 5 years

Population: study terminated early no analysis conducted. Data was not collected from any subject for this Outcome Measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 5 years

Population: study terminated early no analysis conducted. Data was not collected from any subject for this Outcome Measure.

Cumulative incidence approach (Kaplan-Meier \[K-M\] plots and Cox proportional hazard modeling) will be used to estimate distant failure rates.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 5 years

Population: study terminated early no analysis conducted. Data was not collected from any subject for this Outcome Measure.

Cumulative incidence approach (K-M plots and Cox proportional hazard modeling) will be used to estimate disease-specific survival.

Outcome measures

Outcome data not reported

Adverse Events

Treatment (External Beam Radiation Therapy)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Mitchell Kamrava, MD

UCLA

Phone: 310-825-9775

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place